PCM
JNCE

PenderFund Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

PenderFund Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-246,310
Closed -$616K – 150
2023
Q1 		$616K Buy
+246,310
New +$305K 0.19% 82

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

PenderFund Capital Management's JNCE Position: Q2 2023 in Review

PenderFund Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 246,310 shares — an estimated $616K sold.

PenderFund Capital Management first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $616K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • PenderFund Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 246,310 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $616K.
  • PenderFund Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • PenderFund Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $616K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on PenderFund Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.